@Davisite, Daniel, based on the two Sheba trial results, Bisantrene worked miracles with EMD patients (this is, AML patients whose cancer has metastasised) and was pretty ordinary for non-EMD patients.
What if RAC's planned AML trial ends up including only or mostly non-EMD AML patients? will that be a fair test for Bisantrene's known powers?
…..
As I understand it, FTO gets especially over-expressed when cancer metastisises, and Bisantrene is very good at lowering FTO expression.
what if the “all comers” solid tumour trial ends up including mostly non-metastasised cancer patients? these would be the wrong patients to show up Bisantrene's special powers, wouldn’t they?
…
I am concerned about which patients you choose for your two trials. There are two issues here: speedy recruitment and selecting the right kind of patient.
@Davisite, Daniel, based on the two Sheba trial results,...
-
- There are more pages in this discussion • 338 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |